Department of General Surgery, 198153Nanfang Hospital, 70570Southern Medical University, Guangzhou, China.
The First Clinical Medical School, 70570Southern Medical University, Guangzhou, Guangdong, China.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221090353. doi: 10.1177/15330338221090353.
The prognosis of advanced gastric cancer (AGC) is extremely poor, and the therapeutic effect of traditional palliative chemotherapy is far from satisfactory. To overcome this bottleneck, palliative surgery resection, perioperative chemotherapy combined with surgical resection, hyperthermic intraperitoneal chemotherapy (HIPEC), pressurized intraperitoneal aerosol chemotherapy (PIPAC), radiation therapy, molecular-targeted therapy have been explored in AGC. Although considerable progress has been achieved, there is still no overwhelming therapeutic method. Due to the high heterogeneity of AGC, it is particularly vital to reshaped the paradigm of gastric cancer therapy according to the characteristics of clinical classifications and molecular subtypes.
晚期胃癌（AGC）的预后极差，传统的姑息性化疗疗效远不能令人满意。为了克服这一瓶颈，姑息性手术切除、围手术期化疗联合手术切除、腹腔内热灌注化疗（HIPEC）、腹腔内加压气溶胶化疗（PIPAC）、放疗、分子靶向治疗等方法已在 AGC 中进行了探索。尽管取得了相当大的进展，但仍没有一种压倒性的治疗方法。由于 AGC 的高度异质性，根据临床分类和分子亚型的特点重塑胃癌治疗模式尤为重要。
